Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma

Fig. 5

NRPa-308-dependent inhibition of cell proliferation relies mainly on NRP2 in 786-O cells. a Effects of NRPa-308 on cell viability of 786-O cells, of two independent NRP1 (#NRP1 2.2 and #NRP1 2.7) KO clones and of two independent NRP2 (#NRP2 2.3 and #NRP2 2.28) KO clones, measured by MTT assays, are represented to determine NRPa-308 specificity to NRP1 and/or to NRP2. b Clonogenic tests were performed on control 786-O, NRP1- and NRP2-KO cells in the presence of NRPa-308 (0.2 μM) for 6 days or following 6 days treatment then a 29 days’ period without NRPa-308 (0.2 μM). c The percentage of inhibition of VEGFA binding to NRP1 and NRP2 and of VEGFC binding to NRP2 at different concentration of NRPa-308 is presented. *p < 0.05; **p < 0.01

Back to article page